SCHEMBL23833558

SCHEMBL23833558

CNS(=O)(=O)c1cnc(Cl)cc1C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.43
KMT2A Q03164 3/20 0.40
GAA P10253 2/20 0.39
ALDH1A1 P00352 2/20 0.36
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA3 P07451 1/20 0.36
CA4 P22748 1/20 0.36
CA6 P23280 1/20 0.36
CA5A P35218 1/20 0.36
CA7 P43166 1/20 0.36
CA9 Q16790 1/20 0.36
CA13 Q8N1Q1 1/20 0.36
CA14 Q9ULX7 1/20 0.36
CA5B Q9Y2D0 1/20 0.36
TNNI3K Q59H18 2/20 0.36
MEN1 O00255 1/20 0.35
HTT P42858 2/20 0.35
KDM4E B2RXH2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23833535 0.79 L3MBTL1 (0.41) LMNAKMT2AGAAALDH1A1MEN1
SCHEMBL3019043 0.79 ALDH1A1 (0.34) KMT2AGAAALDH1A1MEN1HTT
SCHEMBL30094575 0.79 L3MBTL1 (0.41) LMNAKMT2AGAAALDH1A1MEN1
SCHEMBL23833619 0.79 ALDH1A1 (0.47) LMNAKMT2AGAAALDH1A1MEN1
SCHEMBL23833649 0.78 PDIA6 (0.41) LMNAALDH1A1CA12CA1CA2
SCHEMBL30096955 0.78 PDIA6 (0.41) LMNAALDH1A1CA12CA1CA2
SCHEMBL23833645 0.78 CYP3A4 (0.49) LMNAKMT2AALDH1A1CA12CA1
SCHEMBL23845694 0.76 CDK1 (0.34) KMT2AGAAALDH1A1HTTKDM4E
SCHEMBL26608096 0.75 TSHR (0.45) LMNAKMT2AALDH1A1MEN1KDM4E
SCHEMBL30858406 0.74 POLB (0.41) LMNAKMT2AALDH1A1MEN1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4121426-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE Akebia Therapeutics Inc. (US) 2023-01-25 EP disclosed
WO-2021188938-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE AKEBIA THERAPEUTICS, INC. (US) 2021-09-23 WO disclosed